Pharma Industry

As obesity medications gain popularity, many older Americans support coverage — but not higher premiums.

Policy center argues patients around the world benefit when Americans pay more than their fair share for research and medicines.

HELP Committee Senators press Trump’s FDA pick on the cancelled vaccine advisory meeting, mifepristone access, transparency and agency layoffs.

President Trump says it’s necessary to impose extra costs on goods from Canada, Mexico and China. What does that mean for the health care sector? Potentially, a lot.

Executive order says HHS will ‘rapidly enforce’ price disclosures by hospitals, health insurers.

UCLA research highlights the widespread use of non-evidence-based treatments during the COVID-19 pandemic, raising concerns about the role of misinformation and health care spending.

Both sides support revising laws for PBM market, but Democrats and Republicans disagree on potential Medicaid changes.

Prevention beats treatment for everyone — patients, payers and investors.

A study of the medical economics of ultraprocessed foods, diabetes and pharmaceutical revenues.

A discussion about the Medicare Drug Price Negotiation Program with Adina Lasser, director of public policy and government affairs with the Alliance for Aging Research.

A discussion about the Medicare Drug Price Negotiation Program with Adina Lasser, director of public policy and government affairs with the Alliance for Aging Research.

What new treatments mean for practices and patients.

A discussion about the Medicare Drug Price Negotiation Program with Adina Lasser, director of public policy and government affairs with the Alliance for Aging Research.

A discussion about the Medicare Drug Price Negotiation Program with Adina Lasser, director of public policy and government affairs with the Alliance for Aging Research.

A discussion about the Medicare Drug Price Negotiation Program with Adina Lasser, director of public policy and government affairs with the Alliance for Aging Research.

A discussion about the Medicare Drug Price Negotiation Program with Adina Lasser, director of public policy and government affairs with the Alliance for Aging Research.

A discussion about the Medicare Drug Price Negotiation Program with Adina Lasser, director of public policy and government affairs with the Alliance for Aging Research.

An expert on antimicrobial resistance discusses how it involves patients in local doctors’ offices and around the world.

Study examined Amazon’s RxPass to see how it affected medication adherence and cost

An infectious disease expert describes the state of AMR – and how to fight it.

An infectious disease expert describes the state of AMR – and how to fight it.

An infectious disease expert describes the state of AMR – and how to fight it.

An infectious disease expert describes the state of AMR – and how to fight it.

An infectious disease expert describes the state of AMR – and how to fight it.

An infectious disease expert describes the state of AMR – and how to fight it.

An infectious disease expert describes the state of AMR – and how to fight it.

Proponents say the surgical procedures are underutilized and misunderstood in contemporary medicine.

With high demand but high prices for antiobesity drugs, patients may fall for phony pharmaceuticals.

AP-NORC survey measures approval ratings.

GLP-1 drugs have proven effective in weight loss, but factors like insurance, what industry you work in, or gender, can all affect access